BIO International is the widest deal-making floor in the industry: corporate development, licensing, partnering, and investment conversations across every therapeutic area and company stage, alongside the CROs, CDMOs, and tools vendors that sell into that audience. A booth or a confirmed partnering meeting here is a real, budgeted decision made months ahead, which makes it one of the clearest go-to-market signals on the whole calendar.
What BIO International is
Run by the Biotechnology Innovation Organization, BIO International is the broadest general biotech and pharma show in the US, not tied to a single therapeutic area or function. It draws corporate development, business development, licensing, and executive leadership from biotech and pharma companies, plus investors evaluating deals, alongside the full services and supply ecosystem, CROs, CDMOs, specialty manufacturers, and life science tools and technology vendors, that sells into them.
Because it is not filtered by therapeutic area or function, BIO is less precisely targeted than a disease-specific meeting like ASCO or a function-specific one like SCOPE Summit. What it offers instead is breadth: it is often the single best place to check in on an account's general business-development posture, regardless of what they are working on.
The GTM signal at BIO
Exhibiting is the strongest signal here, for the same reason it matters at any show: it reflects a real, company-level budget commitment made well in advance. A confirmed BIO One-on-One Partnering meeting is arguably just as strong a signal at BIO specifically, since both sides had to actively request and confirm the meeting rather than simply show up. A named speaker on the agenda is the next-sharpest hook: a specific person, topic, and date, all public ahead of the talk. For the full framework on ranking and timing these signals, see selling around life science conferences.
The outreach window
The partnering system and exhibitor list both open for scheduling and publication well before the show, typically several weeks out, which is when serious attendees start locking in who they need to meet. That is the highest-leverage point to reach out: name the show, propose a specific meeting slot or a call beforehand, and be direct about why you want to meet. Outreach during the show itself still works but competes with a packed partnering schedule; the useful follow-up window after BIO closes is measured in a few weeks, not months, before the reference to the show stops reading as timely.
Who this matters most for
BIO's breadth makes it relevant across segments, but the angle differs. A CRO gets the most out of tracking sponsor-side biotech and pharma exhibitors and partnering activity broadly, since BIO is not filtered to a single therapeutic area. A CDMO should watch which companies are visibly courting manufacturing and supply partners on the floor, a signal that often precedes a formal RFP. A tools or services vendor will usually find BIO less precisely targeted than a discipline-specific show, but still worth tracking for general account activity and new-company formation news that surfaces around the show.